GlassScriptPhysician profile
Pedro Mercado
NPI 1366890055
$3,843.26
in general payments reported to CMS, 2019-2025
16 companies · $988 in 2025
The $988 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $772 · 2023: $254 · 2024: $733 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,182.55 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $703.24 | 2021-2025 | Tezspire, Breztri |
| Lilly USA, LLC | $577.15 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $181.76 | 2022-2024 | |
| Glaxosmithkline, LLC. | $139.62 | 2022-2025 | Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $131.72 | 2024 | Fanapt |
| Amgen INC. | $125.00 | 2021 | |
| Verona Pharma, INC. | $124.61 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $123.25 | 2025 | Rexulti |
| United Therapeutics Corporation | $112.05 | 2025 | Tyvaso |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.01 | 2025 | Xifaxan |
| Coloplast Corp | $108.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $108.54 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $74.59 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.54 | 2023 | Spiriva Respimat, Stiolto Respimat |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $16.98 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.